Aeterna Zentaris Inc
F:ET8
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.54
1.67
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
Aeterna Zentaris Inc
F:ET8
|
7.7m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.4B USD |
Loading...
|
Market Distribution
| Min | -9 940 586.9% |
| 30th Percentile | -85.9% |
| Median | -7.8% |
| 70th Percentile | 5.5% |
| Max | 60 777.6% |
Other Profitability Ratios
Aeterna Zentaris Inc
Glance View
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Aeterna Zentaris Inc is -193.6%, which is above its 3-year median of -269.9%.
Over the last 3 years, Aeterna Zentaris Inc’s Net Margin has increased from -199.2% to -193.6%. During this period, it reached a low of -434% on Dec 31, 2022 and a high of -53.9% on Dec 31, 2023.